You are here: Industry Insights > Novartis

News List

Novartis Expands with Kymriah Manufacturing Site in Asia americanpharmaceuticalreview
November 11, 2020
Novartis announced the receipt of marketing authorization from Japan’s Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and Innovation at Kobe (FBRI) to manufacture and supply commercial Kymriah® (tisagenlecleucel) for..
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS) worldpharmanews
November 10, 2020
Novartis announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome.
Novartis’ Cosentyx reduces synovitis in new psoriatic arthritis study pharmatimes
November 06, 2020
Novartis’ interleukin-17A (IL-17A) Cosentyx (secukinumab) demonstrated early synovitis reduction in patients with active psoriatic arthritis in the phase IIIb ULTIMATE study.
Novartis, Molecular Partners to develop two DARPin Therapies for COVID-19 americanpharmaceuticalreview
November 06, 2020
Novartis and Molecular Partners announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP04
Financial Report: Novartis contractpharma
November 06, 2020
Pharmaceutical sales up 2% driven by Entresto, Cosentyx and Zolgensma.
Novartis Expands Kymriah Manufacturing Footprint contractpharma
November 05, 2020
Novartis has received marketing authorization from Japan’s Ministry of Health, Labor and Welfare (MHLW) for Foundation for Biomedical Research and Innovation at Kobe (FBRI) to manufacture and supply commercial Kymriah (tisagenlecleucel) for patients ...
Novartis sets sights on potential COVID-19 antivirals from Molecular Partners pharmatimes
October 30, 2020
Swiss pharma company Novartis has inked an option and license agreement with Molecular Partners to develop, manufacture and commercialise the latter’s anti-COVID-19 DARPin programme.
Novartis and Molecular Partners collaborate on anti-Covid-19 programme pharmaceutical-technology
October 30, 2020
Novartis and Molecular Partners have entered into a collaboration in the form of an option and license agreement for the latter’s anti-COVID-19 DARPin programme.
REGENXBIO Achieves $80M Novartis Milestone contractpharma
October 29, 2020
Zolgensma, which leverages REGENXBIO's NAV AAV9 vector, reaches $1 billion in sales.
Novartis’ rare renal disease candidate shows promise in phase II pharmatimes
October 29, 2020
Interim analysis results for Novartis’ rare renal disease candidate iptacopan proved promising in a phase II study of the investigational drug.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page